XTX Topco Ltd Sells 34,661 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

XTX Topco Ltd decreased its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 75.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,256 shares of the biopharmaceutical company's stock after selling 34,661 shares during the period. XTX Topco Ltd's holdings in Celldex Therapeutics were worth $284,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC raised its holdings in Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 878 shares in the last quarter. Headlands Technologies LLC bought a new position in Celldex Therapeutics in the 4th quarter worth $81,000. KBC Group NV lifted its position in Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 1,647 shares during the last quarter. AlphaQuest LLC boosted its holdings in Celldex Therapeutics by 171.0% during the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock valued at $108,000 after acquiring an additional 2,705 shares during the period. Finally, Aristides Capital LLC acquired a new stake in shares of Celldex Therapeutics in the fourth quarter valued at about $202,000.

Celldex Therapeutics Stock Down 2.7 %

Celldex Therapeutics stock traded down $0.56 on Thursday, hitting $20.28. The company's stock had a trading volume of 117,391 shares, compared to its average volume of 881,844. Celldex Therapeutics, Inc. has a one year low of $14.40 and a one year high of $47.00. The firm has a market cap of $1.35 billion, a P/E ratio of -7.90 and a beta of 1.59. The company has a fifty day moving average price of $19.11 and a 200-day moving average price of $23.34.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts' consensus estimates of ($0.73) by $0.02. The business had revenue of $1.18 million for the quarter, compared to analysts' expectations of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. Analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on CLDX. UBS Group initiated coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They set a "buy" rating and a $44.00 price objective for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. The Goldman Sachs Group reduced their price objective on Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Morgan Stanley began coverage on shares of Celldex Therapeutics in a research report on Thursday, March 20th. They set an "overweight" rating and a $46.00 target price on the stock. Finally, Canaccord Genuity Group initiated coverage on shares of Celldex Therapeutics in a report on Monday. They issued a "buy" rating and a $64.00 price target for the company. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $55.30.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.